Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Liabilities and Shareholders Equity (2018 - 2025)

Avai Bio's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $322014.0 for Q1 2024.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 33.36% to $322014.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $1.2 million, a 8.06% decrease, with the full-year FY2024 number at $322014.0, up 33.36% from a year prior.
  • Liabilities and Shareholders Equity hit $322014.0 in Q1 2024 for Avai Bio, up from $291246.0 in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AVAI hit a ceiling of $816269.0 in Q3 2020 and a floor of $241460.0 in Q1 2023.
  • Historically, Liabilities and Shareholders Equity has averaged $431378.3 across 5 years, with a median of $363739.0 in 2022.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 3764.43% in 2020 and later plummeted 46.89% in 2023.
  • Tracing AVAI's Liabilities and Shareholders Equity over 5 years: stood at $634232.0 in 2020, then rose by 28.7% to $816269.0 in 2021, then tumbled by 65.1% to $284890.0 in 2022, then increased by 2.23% to $291246.0 in 2023, then grew by 10.56% to $322014.0 in 2024.
  • Business Quant data shows Liabilities and Shareholders Equity for AVAI at $322014.0 in Q1 2024, $291246.0 in Q4 2023, and $265061.0 in Q3 2023.